Clinical Trials
13 trialsNCT06783348 2026-06-04
RENALUT
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Recruiting
NCT06632977 2026-06-02
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT05849298 2026-05-27
PSMACare
Novartis
Phase 2 Active not recruiting
NCT05114746 2026-05-08
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in Japan
Novartis
Phase 2 Completed
NCT06852820 2026-05-08
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT07025512 2026-05-08
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06894511 2026-05-01
PSMAndARPI
Novartis
Phase 2 Active not recruiting
NCT07047118 2026-05-01
A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis
Phase 2 Active not recruiting
NCT07550517 2026-04-24
PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Not yet recruiting
NCT05766371 2026-04-17
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT04663997 2026-03-27
177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
NCT06526299 2026-03-24
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease
University of Washington
Phase 2 Recruiting
NCT06288113 2026-03-13
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting